Cell Therapy CDMOs with Clean FDA Inspection History

· updated as new inspection, certificate, and trial data enters the platform
27
CDMOs tracked
27
Fully scored
16
With FDA records
67
FDA inspections
111
EMA/MHRA GMP certs

Cell therapy CDMOs manufacture living products — CAR-T, TCR, NK, and stem-cell therapies — where the process is the product. Autologous programs add patient-scheduling and chain-of-identity demands that allogeneic, batch-based programs avoid.

The right cell therapy CDMO depends on autologous vs allogeneic experience, vector sourcing, closed-system processing, and cold-chain logistics. The rankings below score each CDMO on FDA inspections, GMP certification, clinical activity, and capacity.

FDA inspection outcomes across these CDMOs: 31 NAI (no action), 35 VAI (voluntary action), 1 OAI (official action). Leading inspection & GMP sites: United States (46), Denmark (23), Germany (19), Ireland (17), UNITED KINGDOM (15).

Last updated 2026-11-20. Sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.

Ranked by Signal Score (0–100). Fully evidenced marks a CDMO scored on all four pillars with at least one confirmed clinical program. Partly scored and profile-only CDMOs follow the scored rows. How we score

Showing all operator types.

# CDMO Signal Score Quality FDA · GMP Last FDA inspection Capacity Programs
1
BMS
Bothell, WA · Warren, NJ
Fully evidenced
In-house manufacturer
87.0 97.2 8 insp · 2 GMP 2026-04-28 · NAI — 585 programs
2
CR
Newbury Park, CA · Memphis, TN · Keele, UK · Rockville, MD
86.3 99.2 9 insp · 11 GMP 2026-05-01 · NAI Limited —
3
COH
Duarte, CA
Fully evidenced
Academic / national centre
84.0 97.3 3 insp · 0 GMP 2025-08-20 · VAI — 213 programs
4
TK
Boston, MA · Zurich, CH
Fully evidenced
Also makes its own products
83.4 100.0 4 insp · 20 GMP 2026-04-10 · NAI — 100 programs
5
MN
Philadelphia, PA · Allendale, NJ · Munich, DE · Yokohama, JP
83.1 99.2 3 insp · 4 GMP 2025-11-25 · NAI Limited —
6
WB2
Shanghai, CN · Wuxi, CN
82.7 99.6 1 insp · 4 GMP 2026-07-03 · VAI — —
7
MK
Darmstadt, DE · St. Louis, MO
Hiring · 8 open roles
Fully evidenced
Also makes its own products
81.9 98.8 2 insp · 2 GMP 2025-04-28 · VAI — 22 programs
8
SC
Prague, Czech Republic
81.6 100.0 0 insp · 5 GMP None on file — —
9
EF
Planegg, DE · San Diego, CA
81.6 100.0 7 insp · 0 GMP 2026-05-15 · NAI — —
10
CF
Les Ulis, FR
80.3 100.0 0 insp · 4 GMP None on file — —
11
SG
Bengaluru, India
Hiring · 4 open roles
80.3 100.0 3 insp · 0 GMP 2025-02-20 · NAI — —
12
AG
Longmont, CO · Milan, IT · Copenhagen, DK · Chiba, JP
Hiring · 38 open roles
Fully evidenced
79.9 99.8 4 insp · 27 GMP 2026-05-29 · NAI Available 2 programs
13
SK
Dublin, Ireland. Rancho Cordova, CA. King of Prussia, PA. Houston, TX. Korea. France.
79.5 100.0 — None on file Available —
14
RC
Edinburgh, UK · Hopkinton, MA
Hiring · 8 open roles
79.3 96.8 1 insp · 1 GMP 2025-01-21 · VAI Available —
15
NG
Leiden, NL
78.1 100.0 0 insp · 1 GMP None on file — —
16
CE
Basel, Switzerland
Hiring · 4 open roles
78.1 100.0 0 insp · 1 GMP None on file — —
17
XP
Bristol, United Kingdom
78.1 100.0 0 insp · 1 GMP None on file — —
18
GP
San Diego, CA
78.1 100.0 0 insp · 1 GMP None on file — —
19
CS
Los Angeles, CA
Hiring · 1 open role
Fully evidenced
Academic / national centre
77.3 92.9 2 insp · 0 GMP 2025-03-14 · NAI — 34 programs
20
SY
Stirling, United Kingdom
76.8 100.0 1 insp · 8 GMP 2025-01-31 · NAI — —
21
CY
Toulouse, FR
76.8 100.0 0 insp · 2 GMP None on file — —
22
CN
Luxembourg, LU
76.8 100.0 0 insp · 1 GMP None on file — —
23
HH
London, United Kingdom
76.8 100.0 0 insp · 4 GMP None on file — —
24
BC
Bengaluru, India
Hiring · 48 open roles
75.7 93.1 7 insp · 2 GMP 2025-09-03 · VAI — —
25
NR
San Diego, CA · Boston, MA · RTP, NC · Philadelphia, PA
Hiring · 100+ open roles
Fully evidenced
73.6 95.6 1 insp · 0 GMP 2025-01-21 · VAI Available 9 programs
26
MB
Bergisch Gladbach, Germany
Fully evidenced
73.0 100.0 0 insp · 2 GMP None on file — 8 programs
27
Basel, Switzerland
Hiring · 100+ open roles
Fully evidenced
72.8 86.6 11 insp · 8 GMP 2025-09-29 · VAI — 1 program
How we score CDMOs →

What to evaluate in a Cell Therapy CDMO

Autologous vs allogeneic
Autologous needs per-patient scheduling, chain-of-identity, and short turnaround; allogeneic needs scalable batch processing and a master cell bank strategy. Pick a CDMO proven in your model.
Vector & raw materials
Most cell therapies need a viral vector. Confirm whether the CDMO makes vector in-house or coordinates an external supplier, and how that affects timelines.
Closed-system & cleanrooms
Closed, automated processing reduces contamination risk and labor. Ask about cleanroom grade, automation platforms, and parallel-suite capacity.
Cold chain & logistics
Cryopreservation and chain-of-custody are critical for living cells. Evaluate the CDMO's cold-chain and apheresis-to-infusion logistics.

Cell Therapy CDMOs — Frequently Asked Questions

Who are the top Cell Therapy CDMOs?
Among Cell Therapy manufacturers with a fully evidenced Signal Score (all four pillars and at least one ClinicalTrials.gov match), the highest are Bristol Myers Squibb (CGT Mfg), City of Hope (T Cell Manufacturing), Takeda. The table above is the full list. CDMOs cannot pay to change a score.
How many Cell Therapy CDMOs have FDA inspection records?
CDMO Signal tracks 16 Cell Therapy CDMOs with FDA inspection records and 111 EMA/MHRA GMP certificates across the group.
What should I look for in a cell therapy CDMO?
Match the CDMO to your model: autologous needs chain-of-identity and fast turnaround; allogeneic needs scalable batch processing. Confirm vector sourcing, closed-system processing, cold-chain logistics, and a clean FDA and EMA/MHRA record.
Do cell therapy CDMOs make their own viral vectors?
Some do in-house; others coordinate an external vector supplier. In-house vector can shorten timelines and simplify supply, but a strong external partner is common. Check each profile's modality coverage above.
Related modalities
Lentiviral Vector CDMOs CAR-T CDMOs Gene Editing CDMOs
Other Modalities
AAV CAR-T Lentiviral mRNA/LNP Plasmid DNA Biologics Oligo/ASO Adenoviral Gene Editing Exosome Recombinant Proteins ADC Gene Therapy Cell & Gene Therapy Viral Vector